Epidemiology: Data from Cancer Registries

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Recent advances in the cancer treatment and the resulting increase in patient survival have led to greater scientific interest in multiple primary malignancies (MPM). It is now recognized that longer survival combined with the administration of active but toxic therapeutic regimens has made patients more prone to develop a “second primary cancer,” as a consequence of therapy (e.g., thyroid cancer in lymphoma patients treated with radiotherapy) or of longer exposure to risk factors [1].